DC FieldValueLanguage
dc.contributor.authorSiafarikas, Christos-
dc.contributor.authorKaramanakos, George-
dc.contributor.authorMakrilakis, Konstantinos-
dc.contributor.authorTsolakidis, Anastasios-
dc.contributor.authorMathioudakis, Konstantinos-
dc.contributor.authorLiatis, Stavros-
dc.date.accessioned2025-03-09T18:15:38Z-
dc.date.available2025-03-09T18:15:38Z-
dc.date.issued2024-04-16-
dc.identifierscopus-85191370845-
dc.identifier.issn1439-3646-
dc.identifier.issn0947-7349-
dc.identifier.other85191370845-
dc.identifier.urihttps://uniwacris.uniwa.gr/handle/3000/3025-
dc.description.abstractObjectives: The aim of this study was to investigate the prevalence and incidence of medication-treated diabetes mellitus and the evolving patterns of glucose-lowering treatments, the year before and, during the first two years of the COVID-19 pandemic. Methods: Data from the Greek electronic prescription database were analyzed for the years 2019, 2020, and 2021. The study population included individuals with active social security numbers. Prevalence and incidence rates were calculated based on the dispensing of glucose-lowering medications, according to their unique ATC (anatomical therapeutic chemical) code. Results: The study population comprised 10,289,140 individuals in 2019, 10,630,726 in 2020, and 11,246,136 in 2021. Diabetes prevalence rates were 8.06%, 6.89%, and 7.91%, and incidence rates were 16.8/1000, 8.6/1000, and 13.4/1000 individuals, respectively. Metformin was the most prescribed medication, and newer classes, like SGLT-2 inhibitors and GLP-1 receptor agonists exhibited increasing trends. Conclusions: The study identified a decrease in medication-prescribed diabetes prevalence and incidence during the initial year of the COVID-19 pandemic, attributed to healthcare access restrictions. Subsequently, figures returned close to baseline levels. Glucose-lowering medication trends reflected adherence to local and international guidelines, with metformin as the cornerstone, and increasing preference for newer classes such as GLP-1 receptor agonists and SGLT-2 inhibitors.en_US
dc.language.isoenen_US
dc.relation.ispartofExperimental and Clinical Endocrinology and Diabetesen_US
dc.titlePrevalence and incidence of medication-treated diabetes and pattern of glucose-lowering treatment during the COVID-19 pandemic: real-world data from the electronic Greek prescription databaseen_US
dc.typeArticleen_US
dc.identifier.doi10.1055/a-2307-4631en_US
dc.identifier.scopus2-s2.0-85191370845-
dcterms.accessRights0en_US
dc.relation.deptDepartment of Archival, Library and Information Studiesen_US
dc.relation.facultySchool of Administrative, Economics and Social Sciencesen_US
dc.relation.volume132en_US
dc.relation.issue9en_US
dc.identifier.spage515en_US
dc.identifier.epage521en_US
dc.collaborationUniversity of West Attica (UNIWA)en_US
dc.subject.fieldMedical and Health Sciencesen_US
dc.journalsSubscriptionen_US
dc.publicationPeer Revieweden_US
dc.countryGreeceen_US
local.metadatastatusverifieden_US
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.languageiso639-1en-
item.grantfulltextnone-
crisitem.author.deptDepartment of Archival, Library and Information Studies-
crisitem.author.facultySchool of Administrative, Economics and Social Sciences-
crisitem.author.orcid0000-0001-7364-4542-
crisitem.author.parentorgSchool of Administrative, Economics and Social Sciences-
Appears in Collections:Articles / Άρθρα
CORE Recommender
Sorry the service is unavailable at the moment. Please try again later.
Show simple item record

Page view(s)

13
checked on Apr 8, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.